Adicet Bio, Inc. (ACET)

NCM – Real Time Price. Currency in USD

8.23

0.00 (0.00%)

Market open: Aug 12, 2026, 2:17 PM EDT

8.48

+0.25 (3.03%)

Previous after-hours: Aug 11, 2026, 4:22 PM EDT

11.08.2026

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

Adicet Bio NASDAQ: ACET expects to report clinical data this quarter for its lead autoimmune program, ADI-001, also known as prula-cel, including results in lupus nephritis (LN) and systemic lupus erythematosus (SLE), Chief Executive Officer Chen Schor said at the 46th Annual Canaccord Genuity Growth Conference.

10.08.2026

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

05.08.2026

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the second quarter ended June 30, 2026. “At Adicet, we continue to advance prula-cel toward our next important clinical milestone, with a Phase 1 clinical update now expected in the third quarter of 2026. The additional f.

Videos

No Data

There is no data to display

Press releases

05.08.2026

Adicet Bio, Inc. (ACET)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Adicet Bio, Inc. (ACET)

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Search stocks

Adicet Bio, Inc. (ACET)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Adicet Bio, Inc. (ACET)

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Adicet Bio Eyes Key Lupus Data This Quarter for Off-the-Shelf Cell Therapy

All You Need to Know About Adicet Bio (ACET) Rating Upgrade to Buy

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates

Videos

No Data

Press releases

Adicet Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates